Methcathinone
Viewing r1 — May 3, 2026 — CURRENT
Back to HistoryInteractions, related substances, and reports reflect the current entry and are not shown for historical revisions.
Methcathinone — ephedrone, cat — is a synthetic stimulant of the cathinone class. It is the β-keto structural analog of methamphetamine, roughly twice as potent as amphetamine in animal models.[1] Methcathinone is a dopamine and NET substrate, producing its effects by forcing these neurotransmitters out of nerve terminals into the synapse.[2][3]
Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
First synthesized at Parke-Davis in 1928[4] and briefly investigated as an antidepressant in the Soviet Union,[5] methcathinone never reached clinical use. Clandestine production spread through the USSR by the 1970s and reached the United States by the late 1980s, prompting DEA Schedule I placement in 1993.[6] Its contemporary significance centers on the devastating manganese-induced parkinsonism epidemic among intravenous users across Eastern Europe.[7]
Subjective effects include euphoria, increased energy, confidence, wakefulness, and compulsive redosing.[8][5] The experience is one of driven, focused stimulation — energized alertness and inflated self-assurance with minimal empathogenic warmth, closer to Amphetamine's push than mephedrone's glow. Anxiety, paranoia, and agitated overstimulation are characteristic unsought effects, particularly at higher doses and with chronic use.
Methcathinone produces dependence with compulsive redosing,[9] and PET imaging in abstinent users revealed 16–24% reductions in striatal DAT density.[10] The gravest documented risk is route-specific: intravenous use of permanganate-synthesized preparations introduces manganese contamination causing permanent, treatment-resistant parkinsonism[11] — a hazard of the synthesis method rather than the molecule itself. No controlled human studies have been conducted; the entire evidence base rests on animal pharmacology, clinical case reports, and the Eastern European epidemic literature.
History[edit]
Discovery
Methcathinone was first synthesized at Parke-Davis in 1928.[4] During the 1930s and 1940s, Soviet researchers evaluated it as a potential antidepressant, but no therapeutic application materialized.[4][5] Its structural kinship with both amphetamine and cathinone — the principal stimulant alkaloid of the khat plant — was recognized early, placing it at the intersection of two major pharmacological lineages.
Illicit Spread and Scheduling
In the Soviet Union, clandestine methcathinone production emerged by the 1970s, exploiting a straightforward synthesis: pseudoephedrine from over-the-counter cold medicine oxidized with potassium permanganate.[12][7] The first Western pharmacological characterization appeared in 1987, when Glennon and colleagues established methcathinone as a potent amphetamine-like agent through drug discrimination and neurochemical studies.[1] By the early 1990s the compound had surfaced on US clandestine markets — particularly in Michigan[13] — prompting DEA emergency Schedule I placement in 1992, made permanent in 1993.[6]
The Eastern European Epidemic
From the 1990s through the 2010s, an intravenous methcathinone epidemic spread across Estonia, Latvia, Ukraine, Poland, and other former Soviet states.[14][15] The defining consequence was not the stimulant itself but an iatrogenic disaster: residual manganese from the permanganate synthesis accumulated in users' brains, producing a distinctive and largely irreversible parkinsonian syndrome.[7][16] This manganism epidemic — affecting hundreds of individuals across multiple countries — generated a substantial neuroimaging and clinical literature and remains the most extensively documented hazard of methcathinone use.
The name "ephedrone" — predominant in Russian-language drug culture — reflects the compound's origin as an oxidation product of ephedrine or pseudoephedrine. In English, "cat" emerged as the primary street name during the early 1990s US epidemic. The compound's ease of synthesis from over-the-counter cold medication made it notably accessible compared to other stimulants, a factor that drove its adoption among stimulant-seeking populations in Eastern Europe where it was described as cheaper and more available than Amphetamine.[17]
Chemistry[edit]
Structural Class
Methcathinone is a synthetic cathinone — the β-keto (β-oxo) structural analog of methamphetamine and the N-methyl derivative of cathinone, the principal psychoactive alkaloid of the khat plant (Catha edulis). The β-keto group — a carbonyl at the β-carbon position — defines the cathinone class and distinguishes it from the amphetamine series. Despite this structural modification, methcathinone retains high blood-brain barrier permeability.[2]
Molecular Properties
| Molecular formula | C₁₀H₁₃NO |
| Molecular weight | 163.22 g/mol |
The core structure comprises a phenyl ring bearing a propan-1-one chain with an N-methylamino substituent at the α-carbon. This scaffold is shared with mephedrone, methylone, and other synthetic cathinones, differing only in ring substitution and N-alkylation patterns.
Stereochemistry
Methcathinone possesses one chirality center at C-2, yielding two enantiomers: S(-) and R(+). The S(-) form is the more potent behavioral isomer — approximately twice as potent as S(+)-amphetamine and three to five times more potent than R(+)-methcathinone in locomotor and drug discrimination assays.[13] Illicit methcathinone is sold primarily as the S(-) form.[13][3]
Despite this marked behavioral difference, both enantiomers are nearly equally effective as dopamine and NET substrates in vitro, suggesting the potency gap arises from pharmacokinetic factors rather than transporter binding alone.[3]
Pharmacology[edit]
Mechanism of Action
Methcathinone enters presynaptic nerve terminals through the DAT (DAT) and NET (NET), then forces these neurotransmitters out into the synapse — a process called reverse transport or carrier-mediated efflux. This mechanism is shared with amphetamine and methamphetamine.[1][2][3]
Methcathinone is classified among Group 1 cathinones — agents that preferentially release dopamine and norepinephrine, analogous to amphetamine — as distinct from MDMA-like compounds that additionally flood serotonin systems.[2] Its activity at the SERT is more than 63-fold weaker than at DAT and NET,[3] making it a strongly catecholamine-selective stimulant. This selectivity profile is a key predictor of abuse potential within the cathinone series.[18]
Unlike non-β-keto amphetamines, methcathinone does not activate TAAR1 and has negligible interaction with vesicular monoamine transporters.[2] In animal studies, it produces dose-dependent increases in dopamine and serotonin in the nucleus accumbens — the brain's primary reward region.[19][20] The ratio of dopamine to serotonin release correlates positively with abuse-related behavioral effects across the cathinone series.[19]
Pharmacokinetics
No human pharmacokinetic studies for methcathinone have been published. Half-life, bioavailability, peak plasma time, protein binding, and metabolic pathways remain entirely uncharacterized in humans.
The only temporal data come from animal models. In rats receiving methcathinone by injection, behavioral effects appear within five minutes and persist for roughly 60–90 minutes.[21] Total duration of oral effects is estimated at four to six hours based on unverified sources,safety citation needed broadly consistent with the stimulant class but lacking primary human confirmation.
Methcathinone and its metabolites can be detected in urine by GC-MS[22] and in blood and urine by LC-Q/TOF mass spectrometry,[23] confirming systemic absorption and renal excretion.
Neuroscience[edit]
Where It Acts
Methcathinone's primary neural target is the mesolimbic pathway — the circuit running from the ventral tegmental area to the nucleus accumbens that mediates reward and motivation. By forcing dopamine out through the DAT, methcathinone floods this pathway, producing the subjective experience of euphoria, drive, and heightened incentive salience.[19][20]
The high ratio of dopamine to serotonin release distinguishes methcathinone's neurochemical signature from MDMA-like compounds and correlates with abuse-related behavior.[19] Concurrent norepinephrine release drives the sympathomimetic effects — elevated heart rate, blood pressure, and the subjective sense of alert arousal. Dopamine receptor blockade by haloperidol abolishes the methcathinone stimulus in rats, confirming dopamine as the primary mediator of its subjective effects.[21]
Why It Matters
Methcathinone maps cleanly onto the incentive salience model of addiction: mesolimbic dopamine release drives "wanting" — the motivational pull toward drug-associated cues — rather than "liking" or hedonic pleasure per se. The compulsive redosing pattern documented across Eastern European epidemic populations[17][5] is consistent with hypersensitized wanting circuits maintaining drug-seeking even as the hedonic return diminishes.
Repeated exposure produces both tolerance and sensitization simultaneously in animal reward models[9] — acute pleasure fades while motivational drive intensifies, a pattern characteristic of amphetamine-type addiction.
The sole human neuroimaging study (n=4) found 16–24% reductions in striatal dopamine transporter density after approximately three years of abstinence.[10] Whether this finding replicates in larger samples, and whether deficits progress or stabilize after cessation, is unknown.
Subjective Effects[edit]
Methcathinone delivers a catecholaminergic stimulant experience — energized euphoria, sharpened confidence, and driven wakefulness powered by dopamine and norepinephrine release. At lower doses the effect is focused and functional; higher doses compress into a more intense and dysphoric arc where anxiety, paranoia, and agitated overstimulation emerge. Set and setting significantly modulate the balance between prosocial confidence and anxious hypervigilance, particularly as dose or session duration increases.
Within the cathinone series, methcathinone's profile sits closest to amphetamine and methamphetamine — more focused drive than emotional openness, with minimal empathogenic warmth compared to mephedrone or MDMA. The compulsive compulsive redosing urge is a defining behavioral feature, consistent with its high dopamine selectivity.
Effect Grid
At common doses, the full stimulant experience is present: pronounced cognitive euphoria, strong motivation enhancement, marked thought acceleration, and significant wakefulness. Sociability and confidence are heightened. Users report increased energy and reduced fatigue, with a clear sense of stimulation that dominates the experience.
Cardiovascular effects become prominent — tachycardia, noticeable vasoconstriction, and elevated blood pressure. Bruxism (jaw clenching), excessive sweating, and appetite suppression are typical. Compulsive redosing urge may emerge as effects begin to wane.
Sleep is impossible for the duration and several hours beyond. Functional impairment increases due to overconfidence and reduced impulse control despite subjective feelings of enhanced performance.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Touch enhancement · Sound sensitivity · Auditory hallucinations · External hallucinations · Shadow people
Shadow people
Pupil dilation · Insomnia · Physical fatigue · Dry mouth · Restlessness · Excessive sweating · Muscle tension · Dehydration sensation · Body high · Heart rate perception changes · Temperature dysregulation · Spontaneous body sensations · Nausea · Bruxism · Sexual arousal enhancement · Bodily lightness · Respiratory stimulation · Tingling / electric sensations · Trembling · Tactile euphoria · Involuntary body movements · Headache · Vibrations / buzzing · Dizziness · Motor control impairment · Vomiting · Tactile hallucination
Dry mouth · Restlessness · Excessive sweating · Muscle tension · Dehydration sensation · Body high · Heart rate perception changes · Spontaneous body sensations · Nausea · Bruxism · Sexual arousal enhancement · Bodily lightness · Respiratory stimulation · Tingling / electric sensations · Trembling · Tactile euphoria · Involuntary body movements · Headache · Vibrations / buzzing · Dizziness · Motor control impairment · Vomiting · Tactile hallucination
Motivation suppression · Focus enhancement · Motivation enhancement · Information processing enhancement · Analysis enhancement · Cognitive dysphoria · Immersion enhancement · Novelty enhancement · Pattern recognition enhancement · Thought organization · Language enhancement · Thought deceleration · Aesthetic enhancement · Conceptual thinking · Multiple thought streams · Thought connectivity · Memory enhancement · Creativity enhancement · Humor enhancement · Cognitive impairment · Confusion · Openness enhancement · Thought disorganization · Thought loops · Delusions · Delirium
Information processing enhancement · Analysis enhancement · Cognitive dysphoria · Immersion enhancement · Novelty enhancement · Pattern recognition enhancement · Thought organization · Language enhancement · Thought deceleration · Aesthetic enhancement · Conceptual thinking · Multiple thought streams · Thought connectivity · Memory enhancement · Creativity enhancement · Humor enhancement · Cognitive impairment · Confusion · Openness enhancement · Thought disorganization · Thought loops · Delirium
Anhedonia · Dysphoria · Emotional enhancement · Empathy enhancement · Emotional lability · Mania
Empathy enhancement · Emotional lability
Disinhibition · Ego inflation · Flow state · Social connection · Automaticity · Trust enhancement
Automaticity · Trust enhancement
Timeline
First alerts appear as subtle mood lift, mild restlessness, and faint physical energy. Heart rate begins to increase.
Stimulation builds steadily with increasing wakefulness, emerging euphoria, and growing confidence. Cardiovascular activation becomes noticeable — elevated heart rate, vasoconstriction.
Maximum stimulation with pronounced cognitive euphoria, motivation enhancement, thought acceleration, and strong wakefulness. Cardiovascular effects are at their most intense. Compulsive redosing urge may emerge as the peak begins to plateau.
Effects sustain at diminished but clearly perceptible intensity. Stimulation persists with waning euphoria. Sympathomimetic effects (tachycardia, sweating, bruxism) continue.
Gradual return toward baseline with fading stimulation. Irritability, restlessness, and early dysphoria emerge. Appetite begins to return.
Residual effects include low mood, fatigue, reduced motivation, and disrupted sleep architecture. Anhedonia and mild depression may persist for 12–24 hours after strong doses. Appetite returns but may remain suppressed.
Safety[edit]
- Acute toxicity
- Moderate
- Chronic toxicity
- High
- Withdrawal
- Mild
- Tolerance buildup
- moderate
- Tolerance reset
- —
- Physical
- Low
- Psychological
- High
- Compulsive redosing
- High
- Dose escalation
- Moderate
- Cross-tol.
- —
Toxicity
Acute Toxicity
Mouse LD₅₀ for pure methcathinone is 201.7 mg/kg (intraperitoneal).[25] The LD₅₀ of permanganate-synthesized product is substantially lower at 110.2 mg/kg equivalent, reflecting additive manganese toxicity.[25] At high experimental doses, seizures occurred in 74% of mice, with dose-dependent mortality.[25] No human lethal dose data exist and no therapeutic index has been established.safety citation needed
Monoaminergic Neurotoxicity
Both enantiomers damage dopamine neurons in animal models, while S(-)-methcathinone additionally damages serotonin neurons — a property absent from cathinone itself and attributable to the N-methyl group.[26] PET imaging in four abstinent users (mean ~3 years abstinence) showed 24% reduction in caudate and 16% reduction in putamen DAT density,[10] suggesting subclinical dopaminergic injury that may increase vulnerability to age-related motor decline.
Subchronic exposure in rats produced learning and memory decline with structural synaptic damage in the prefrontal cortex and over 1,400 differentially expressed genes identified by transcriptomic analysis.[24]
Manganese Encephalopathy (IV Route)
Intravenous use of methcathinone prepared by potassium permanganate oxidation of pseudoephedrine introduces manganese contamination that causes permanent, largely irreversible parkinsonism. This is the single most dangerous documented consequence of methcathinone use.
The syndrome emerges within months of regular IV use[12][16] and includes slowed movement, abnormal posture, freezing gait, speech difficulties, tremor, and rigidity.[7][27] It has been documented across Estonia, Latvia, Ukraine, Poland, and Ireland.[14][15]
Brain imaging reveals characteristic bilateral bright spots in the globus pallidus on MRI[28] and widespread white matter damage.[29] This form of parkinsonism is mechanistically distinct from Parkinson's disease — it does not involve the same midbrain neuron loss.[11] L-DOPA does not work,[7][11] chelation therapy is generally ineffective,[16] and the condition is largely permanent.[15]
Parkinsonian features occur in approximately half of long-term IV users.[30] Cognitive consequences include decision impairment[31] and measurable neuropsychological deficits.[32][33]
Psychological Risks
Agitation, anxiety, paranoia, and hallucinations are documented psychiatric adverse effects, particularly with heavy or chronic use.[8][5][34] Acute psychosis can emerge during binges, and chronic use is associated with sustained paranoid thinking.
The compulsive redosing pattern carries secondary psychiatric risks: prolonged binges produce sleep deprivation, malnutrition, and social deterioration.[17][5] As a potent dopamine-releasing agent, methcathinone poses theoretical risk for precipitating psychosis in vulnerable individuals, consistent with the amphetamine class.inferred
Tolerance & Dependence
Dependence is documented in clinical case reports, with compulsive IV use and tolerance escalation described throughout the Eastern European epidemic literature.[17] Methcathinone was described as cheaper and more accessible than Amphetamine, driving adoption among stimulant-seeking populations.[17]
In animal studies, repeated methcathinone treatment produced complex dynamics of both tolerance and sensitization.[9] No human withdrawal has been specifically characterized; a stimulant withdrawal profile (fatigue, low mood, excessive sleep) is expected by class but substance-specific data are absent.inferred
Cross-tolerance with Amphetamine, methamphetamine, and other dopamine/norepinephrine releasing agents is expected based on full cross-generalization in animal drug discrimination studies.[21]
Drug Interactions
No published drug interaction studies specific to methcathinone exist. All assessments below are inferred from its pharmacology as a monoamine releasing agent.inferred
The most dangerous predicted interaction is with monoamine oxidase inhibitors (MAOIs). Combined use would produce uncontrolled accumulation of dopamine, norepinephrine, and serotonin — risking dangerous blood pressure spikes, overheating, seizures, and death.
Co-administration with other stimulants (Amphetamine, cocaine, MDMA) poses additive cardiovascular and overheating risk. At higher doses methcathinone releases serotonin,[19][20] making serotonin syndrome plausible when combined with serotonergic drugs (SSRIs, SNRIs, triptans), though no case has been published.
Tricyclic antidepressants and SNRIs may amplify cardiovascular effects through overlapping norepinephrine mechanisms.
Contraindications
No substance-specific contraindication data exist. The following are inferred from its pharmacological class.inferred
Absolute contraindications (class inference):
- Concurrent MAOI therapy — risk of dangerous blood pressure crisis and serotonin syndrome
- Severe heart disease, uncontrolled high blood pressure, or irregular heartbeat — methcathinone's stimulant effects impose acute cardiovascular stress
Relative contraindications (class inference):
- History of psychosis or schizophrenia — dopamine release may trigger or worsen psychotic episodes
- Concurrent stimulant use — additive cardiovascular and overheating risk
- Pregnancy — no reproductive toxicity data exist; class-level risk appliessafety citation needed
Harm Reduction[edit]
Forms & Identification
Methcathinone hydrochloride — the form encountered in illicit production — is typically a white or off-white crystalline powder. The critical identification concern is not substitution with other substances but contamination within the product itself: methcathinone synthesized by permanganate oxidation of pseudoephedrine inevitably contains residual manganese compounds, and no field test can quantify manganese content.
Reagent testing can confirm the presence of a cathinone but cannot distinguish between a clean and a contaminated batch. For IV users in particular, the absence of any practical purity assurance method means every injection carries unknown manganese exposure.
Guidelines
- Test material with a reagent kit to confirm cathinone presence — this rules out gross substitution but will not detect manganese contamination
- Start with the lowest plausible dose and wait for full onset before considering redosing
- Pre-set a hard redosing limit and remove excess material from reach before the session begins
- Avoid intravenous administration — this route carries the highest risk of manganese-induced brain damage from permanganate-synthesized product
- Eat before dosing, as appetite suppression is likely; stay hydrated without overhydrating
- Monitor heart rate; stop activity and seek help if chest pain, severe headache, or irregular heartbeat develops
Set & Setting
The stimulant profile favors environments where elevated heart rate and restless energy can be managed safely. Overstimulating or socially pressured settings amplify anxiety and paranoid ideation — effects that escalate rapidly at higher doses.
A trusted, sober companion reduces risk during first use. Given the strong compulsive redosing urge, setting a firm dose limit before the session and physically separating remaining material reduces the likelihood of unplanned escalation.
Aftercare & integration. The stimulant comedown typically involves fatigue, low mood, irritability, and disrupted sleep. Prioritize rest — avoid the temptation to redose to offset the crash. Eat nutritious food as appetite returns; adequate hydration and B vitamins support recovery.
Sleep disruption may persist for one to two days after a session. Avoid caffeine and additional stimulants during this period. If low mood or anhedonia persists beyond a few days, this signals a need to reassess use patterns rather than a problem to dose through.
Recovery & Support
Methcathinone dependence follows the stimulant pattern: compulsive redosing escalates into binges, tolerance drives dose increases, and the crash between sessions deepens with chronic use. Recognition of this cycle is the first step toward change.
Professional support through addiction medicine or behavioral health services provides the most evidence-based path to recovery. Cognitive behavioral therapy has demonstrated effectiveness for stimulant use disorders. Peer support communities — including SMART Recovery and 12-step programs adapted for stimulant users — offer structured ongoing support. For individuals in the IV methcathinone population who may have developed manganese-related neurological symptoms, neurological evaluation is essential, as motor and cognitive impairments may require specialized rehabilitation.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency:
- Chest pain, severe headache, or irregular heartbeat
- Seizures or loss of consciousness
- Body temperature so high it can be felt through clothing
- Extreme agitation, violent behavior, or psychosis with loss of contact with reality
- Breathing difficulties
Immediate steps:
- 1. Call emergency services if any of the above signs are present
- 2. Move the person to a cool, quiet environment
- 3. If unconscious but breathing, place in the recovery position (on their side, airway clear)
- 4. Do not restrain unless there is immediate danger of self-harm
- 5. Do not induce vomiting
- 6. Monitor breathing and heart rate while waiting for help
What to tell the dispatcher:
- The substance taken (methcathinone or ephedrone), estimated amount, time of last dose, and route of administration
- Current symptoms — especially chest pain, seizures, temperature, or altered consciousness
- Good Samaritan laws in many jurisdictions protect people who call for help during a drug emergency
Legal Status[edit]
Methcathinone is internationally controlled and carries no accepted medical use in any jurisdiction. It is classified under the highest restriction schedules in all countries where it has been specifically scheduled. The compound's simple clandestine synthesis from over-the-counter pseudoephedrine and potassium permanganate has complicated enforcement, particularly in Eastern European countries where the IV epidemic was most severe.
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States | Schedule I (Controlled Substances Act) | Emergency scheduled May 1, 1992; permanently placed in Schedule I in 1993. No accepted medical use; high abuse potential; pharmacological effects similar to amphetamines[6] |
| International | Schedule I (1971 UN Convention on Psychotropic Substances) | Listed alongside other synthetic cathinones under the Convention framework[35] |
| United Kingdom | Class B (Misuse of Drugs Act 1971); Schedule 1 (MDR 2001) | Controlled under synthetic cathinone generic definition[4] |
| Australia | Schedule 9 (Poisons Standard) | Prohibited substance; no permitted use outside approved researchcitation needed |
| Canada | Controlled (CDSA) | Scheduled under the Controlled Drugs and Substances Actcitation needed |
references
- [1] ^abcGlennon RA, Yousif M, Naiman N, Kalix P (1987) Methcathinone: a new and potent amphetamine-like agent. — Pharmacology, Biochemistry, and Behavior PMID:3575369
- [2]
- [3] ^abcdeDavies RA, Baird TR, Nguyen VT, Ruiz B, Sakloth F, Eltit JM, Negus SS, Glennon RA (2020) Investigation of the Optical Isomers of Methcathinone, and Two Achiral Analogs, at Monoamine Transporters and in Intracranial Self-Stimulation Studies in Rats. — ACS Chemical Neuroscience doi:10.1021/acschemneuro.9b00617
- [4]
- [5]
- [6]